Indoco Remedies · NSE: INDOCO · BSE: 532612
Q2 FY21 results · Jul–Sep 2020
Indoco Remedies reported revenue from operations of ₹328.24 crore (up 12.2% from Q2 FY20) and net profit of ₹25.65 crore (up 228.4% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 328.24 | 292.57 | +12.2% | 275.86 | +19.0% |
| Other income | 0.52 | 0.58 | −10.3% | 0.26 | +100.0% |
| Total income | 328.76 | 293.15 | +12.1% | 276.12 | +19.1% |
| Profit before tax | 36.78 | 9.80 | +275.3% | 24.03 | +53.1% |
| Net profit for the period | 25.65 | 7.81 | +228.4% | 17.04 | +50.5% |
| EPS, basic (₹) | 2.78 | 0.85 | +227.1% | 1.85 | +50.3% |
| Net margin (%) | 7.8 | 2.7 | 6.2 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 327.65 | 291.97 | +12.2% | 275.86 | +18.8% |
| Other income | 0.52 | 0.58 | −10.3% | 0.26 | +100.0% |
| Total income | 328.17 | 292.55 | +12.2% | 276.12 | +18.9% |
| Profit before tax | 36.24 | 9.31 | +289.3% | 24.24 | +49.5% |
| Net profit for the period | 25.11 | 7.33 | +242.6% | 17.23 | +45.7% |
| EPS, basic (₹) | 2.72 | 0.80 | +240.0% | 1.87 | +45.5% |
| Net margin (%) | 7.7 | 2.5 | 6.2 |
Consolidated
- Filed with BSE
- 09 Nov 2020, 15:25 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 09 Nov 2020, 15:25 IST
- Board meeting
- 06 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE